Barclays Reiterates Buy Rating on SAB Biotherapeutics, Inc.
Barclays maintains its buy rating on SAB Biotherapeutics, Inc., setting a $13 price target, a 242.11% upside from the current price.
Key Points
- Barclays reiterated its buy rating on SAB Biotherapeutics, Inc. (SABS) with a $13.00 price target on June 24, 2026.
- Barclays's $13 price target implies 242.11% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.80 share price.
- Shares of SABS traded near $3.88 on Wednesday, with a market cap of about $300.5 million and a 52-week range of $1.67 to $6.60.
- Other analysts, like Chardan Capital and Leerink Partners, also maintain a buy rating, with targets of $16.00 and $12.00 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays has reiterated its buy rating on SAB Biotherapeutics, Inc. (NasdaqCM: SABS) with a price target of $13.00. This update came on June 24, 2026, and reflects the firm's confidence in the company's potential.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
SAB Biotherapeutics, Inc. Stock Up 0.3%
Shares of NasdaqCM:SABS traded near $3.88 on Wednesday. SAB Biotherapeutics, Inc. has a market cap of approximately $300.5 million. The company's forward P/E ratio is not meaningful as it isn't profitable, and the beta is 0.55, indicating lower volatility compared to the market. Over the past year, the stock has ranged from a low of $1.67 to a high of $6.60. Its 50-day and 200-day moving averages are $3.69 and $3.51, respectively. The firm boasts a strong current ratio of 11.45 and a quick ratio of 11.06, with a debt-to-equity ratio of 2.72.
$SABS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
SAB Biotherapeutics, Inc. is still in its clinical stages and not profitable, with an EPS of -$0.58. The company reported no net margin and a return on equity of -0.32%. Investors are keeping an eye on its next earnings report, expected on August 11, 2026.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Recent insider activity at SAB Biotherapeutics includes significant buying. On February 3, 2026, CEO Samuel Reich acquired 4.8 million shares, while CFO Lucy To and COO Christoph Lawrence each bought 2.4 million shares. Chief Medical Officer Alexandra Kropotova also bought 2.4 million shares on the same day.
Analysts Set New Price Targets
On June 24, 2026, Barclays reiterated its buy rating for SAB Biotherapeutics with a $13.00 price target. Other analysts are also optimistic. Chardan Capital maintained its buy rating with a $16.00 target on June 17, and Leerink Partners upheld a buy rating with a $12.00 target on June 15. The consensus rating is a strong buy, with a mean price target of $11.00 among 10 analysts.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Miami Beach, Florida. Founded in 2014, the company focuses on developing human polyclonal immunotherapeutic antibodies to treat immune system disorders and infectious diseases. Its leading product candidate, SAB-142, is in Phase 2b clinical trials for autoimmune type 1 diabetes. The company is led by CEO Samuel J. Reich and employs 86 people.
Bottom Line
Barclays' reiteration of a buy rating and a $13 price target on SAB Biotherapeutics, Inc. underscores confidence in the company's future. While the firm is not yet profitable, analysts see potential in its pipeline and ongoing clinical trials. Investors should remember that analyst ratings are based on the latest available information and can change as circumstances evolve.
Get SAB Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SABS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.